Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 11Completed 8Terminated 3Active not recruiting 2Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 37Head & Neck 4Thoracic 2Dermatologic 2Breast 2Sarcoma 1Other solid neoplasm 1NET 1Gynecologic 1Genitourinary 1Endocrine 1CNS 1

Conditions

Breast Neoplasms 849Triple Negative Breast Neoplasms 136Ovarian Neoplasms 55Colorectal Neoplasms 49Carcinoma, Non-Small-Cell Lung 47Neoplasms 43Neoplasm Metastasis 43Prostatic Neoplasms 42Lung Neoplasms 38Melanoma 30Carcinoma, Intraductal, Noninfiltrating 29Uterine Cervical Neoplasms 27Pancreatic Neoplasms 25Colonic Neoplasms 25Stomach Neoplasms 23Squamous Cell Carcinoma of Head and Neck 23Endometrial Neoplasms 23Carcinoma, Renal Cell 23Breast Carcinoma In Situ 22Esophageal Neoplasms 17Urinary Bladder Neoplasms 16Motor Activity 16Inflammatory Breast Neoplasms 16Head and Neck Neoplasms 16Small Cell Lung Carcinoma 15Sarcoma 14Breast Cancer Female 13Brain Neoplasms 12Anatomic Stage I Breast Cancer AJCC v8 12Gastrointestinal Neoplasms 11

Interventions

obinutuzumab 1naptumomab estafenatox 1durvalumab 1Itraconazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Esophageal Squamous Cell Carcinoma × Breast × Clear all
NCT06084481 2026-01-20

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

AbbVie

Phase 1 Active not recruiting
302 enrolled
BreastGastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Biliary Tract Neoplasms, Carcinoma, Hepatocellular, Triple Negative Breast Neoplasms

NCT03983954 2025-11-28

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

NeoTX Therapeutics Ltd.

Phase 1 Active not recruiting
120 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡